The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease

被引:30
|
作者
Pilotto, A
Franceschi, M
Di Mario, F
Leandro, G
Bozzola, L
Valerio, G
机构
[1] San Bortolo Hosp, Dept Geriatr, Vicenza, Italy
[2] Univ Padua, Dept Gastroenterol, I-35100 Padua, Italy
[3] Dept Gastroenterol, Castellana Grotte, Italy
[4] Clin Pathol Unit, Vicenza, Italy
关键词
Helicobacter pylori; peptic ulcer; endoscopy;
D O I
10.1159/000022000
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The objective of this study was to evaluate the long-term efficacy of Helicobacter pylori (HP) eradication treatment in elderly patients with HP-associated peptic ulcer. A total of 56 subjects, 25 affected with gastric ulcer (GU, 9 males, 16 females, mean age 77.8 years, range 67-93) and 31 with duodenal ulcer (DU, 19 males, 12 females, mean age 76.5 years, range 65-87) were confirmed to be HP-positive by gastric histology and the rapid urease test. All patients were then consecutively treated with omeprazole for 4 weeks plus one or two antibiotics for 1 week as anti-HP treatment. Clinical checkups were then performed every 3 months for 1 year for the evaluation of symptoms and clinical recurrences. Endoscopy with gastric biopsies was repeated after 1, 3 and 12 months for the evaluation of ulcer healing, HP infection and chronic gastritis activity. Statistical analysis was performed by means of the Student t test for unpaired data, the Fisher exact test (two-tailed), and the McNemar chi(2) test. After 4 weeks of treatment, endoscopy confirmed healing of the ulcer in all patients, regardless of the treatment used to cure HP infection. Two months after the end of therapy, a total of 44 patients were HP-negative and 12 patients were still HP-positive. During the 1-year follow-up period 1/44 (2.2%) of the HP-eradicated patients and 5/12 (41.6%) of the still HP-positive patients suffered relapses (p = 0.001): the difference between the two groups remained statistically significant when patients were divided into the subgroups, GU (p = 0.01) and DU (p = 0.04). Two months after the end of therapy, there was still a significant reduction of symptoms both in HP-eradicated (p < 0.0000) and in HP-positive (p = 0.002) patients. After 1 year, however, there was a significantly decreased symptomatology only in HP-eradicated subjects (p < 0.0000) and not in patients still HP-positive. After both 2 months and 1 year of follow-up, chronic gastritis activity demonstrated a significant improvement only in HP-eradicated patients (p = 0.0000). In conclusion, the eradication of HP infection significantly improved the long-term clinical outcome of peptic ulcer disease in the elderly, reducing the recurrences of GU and DU, the patient's symptomatology and the histological signs of chronic gastritis activity. The cure of HP infection is, therefore, strongly recommended in elderly patients with HP-associated peptic ulcer disease.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 50 条
  • [31] The evaluation of tissue kallikrein in Helicobacter pylori-associated gastric ulcer disease
    Naidoo, S
    Ramsaroop, R
    Bhoola, R
    Bhoola, KD
    IMMUNOPHARMACOLOGY, 1997, 36 (2-3): : 263 - 269
  • [32] Helicobacter pylori heterogeneity in patients with gastritis and peptic ulcer disease
    Ines Armitano, Rita
    Jose Matteo, Mario
    Goldman, Cinthia
    Wonaga, Andres
    Alberto Viola, Luis
    Zerbetto de Palma, Gerardo
    Catalano, Mariana
    INFECTION GENETICS AND EVOLUTION, 2013, 16 : 377 - 385
  • [33] Treatment of Helicobacter pylori infection in patients with peptic ulcer disease
    Godshall, CJ
    AMERICAN JOURNAL OF SURGERY, 2002, 183 (01): : 2 - 3
  • [34] The profiling of patients with peptic ulcer disease and helicobacter pylori - negative
    Auwyang, Jacobusalbertus
    Kolopaking, Marcellussimadibrata
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 101 - 102
  • [35] Long-term risks of peptic ulcers associated with Helicobacter pylori infection and NSAIDs
    Lew, EA
    Cook, N
    Perez-Perez, G
    Blaser, MJ
    Gaziano, JM
    GASTROENTEROLOGY, 2004, 126 (04) : A1 - A1
  • [36] Helicobacter pylori and peptic-ulcer disease
    Boulton-Jones, JR
    Hawkey, CJ
    LANCET, 2002, 359 (9321): : 1943 - 1943
  • [37] Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain)
    Tefera, S
    Berstad, A
    Bang, CJ
    Nysaeter, G
    Hatlebakk, JG
    Olafsson, S
    Nesje, LB
    Hausken, T
    Berstad, K
    Hundal, O
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1996, 91 (05): : 935 - 941
  • [38] New ses of Helicobacter pylori-associated duodenal ulcer
    Minushkin, ON
    Vasilyeva, NY
    Kudryavtseva, LV
    TERAPEVTICHESKII ARKHIV, 1998, 70 (01) : 37 - 41
  • [39] Peptic ulcer disease associated familial prevalence of oral Helicobacter pylori
    Botha, I
    Smit, S
    Botha, FS
    De Wet, BJP
    Botha, SJ
    JOURNAL OF DENTAL RESEARCH, 2001, 80 (04) : 1362 - 1362
  • [40] Stress, but not Helicobacter pylori, is associated with peptic ulcer disease in a Thai population
    Wachirawat, W
    Hanucharurnkul, S
    Suriyawongpaisal, P
    Boonyapisit, S
    Levenstein, S
    Jearanalsilavong, J
    Atisook, K
    Boontong, T
    Theerabutra, C
    GASTROENTEROLOGY, 2002, 122 (04) : A210 - A210